Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific anti-inflammatories (canakinumab or anakinra for IL-1β inhibition), anticoagulant (heparin), or anti-diabetic drugs in COVID-19 treatment since patients with obesity may benefit to a greater extent from a treatment that modulates these parameters. The gene discussed is IL1B; the disease is obesity disorder.